RenovoRx (RNXT) director adds $10K via rollover IRA private deal

Rhea-AI Filing Summary

RenovoRx director Marton Laurence, through his Laurence Marton Rollover IRA, bought securities in a private placement. The IRA acquired 4,860 warrants and 9,720 shares of RenovoRx common stock for an aggregate purchase price of $10,000.

The warrants are immediately exercisable at $1.9326 per share and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.

Insider Trade Summary

2 transactions reported

Net Buy 2 txns

Insider Marton Laurence

Role Director

Bought 14,580 shs ($0.00)

Type	Security	Shares	Price	Value
Purchase	Warrants	4,860	$0.00	--
Purchase	Common Stock	9,720	$0.00	--

Holdings After Transaction: Warrants — 4,860 shares (Indirect, Laurence Marton Rollover IRA); Common Stock — 9,720 shares (Indirect, Laurence Marton Rollover IRA)

Footnotes (1)

1. The securities were purchased in a private placement on March 20, 2026 for an aggregate of $10,000. The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marton Laurence

(Last) (First) (Middle)

C/O RENOVORX, INC.

2570 W EL CAMINO REAL, SUITE 320

(Street)

MOUNTAIN VIEW CALIFORNIA 94040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026	03/20/2026	P		9,720	A	(1)	9,720	I	Laurence Marton Rollover IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$1.9326	03/20/2026	03/20/2026	P		4,860		(2)	(2)	Common Stock	4,860	(1)	4,860	I	Laurence Marton Rollover IRA

Explanation of Responses:

1. The securities were purchased in a private placement on March 20, 2026 for an aggregate of $10,000.

2. The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.

	/s/ Laurence Marton	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did RenovoRx (RNXT) director Marton Laurence buy in this Form 4?

Director Marton Laurence, via his rollover IRA, bought 4,860 warrants and 9,720 RenovoRx common shares. The purchase occurred in a private placement and totals 14,580 underlying shares, increasing his indirect economic exposure to the company.

How much did the RenovoRx (RNXT) insider pay in this private placement?

The rollover IRA associated with director Marton Laurence paid an aggregate $10,000 in the private placement. This amount covers both the 4,860 warrants and 9,720 common shares reported, reflecting a relatively small but clear insider capital commitment.

What are the key terms of the RenovoRx (RNXT) warrants purchased?

The warrants are immediately exercisable at an exercise price of $1.9326 per share. They expire on the earlier of March 30, 2029, or 30 days after RenovoRx reports at least $1.5 million in quarterly product sales revenue in a periodic report.

Is the RenovoRx (RNXT) insider purchase direct or through another entity?

The purchase is indirect, made through the Laurence Marton Rollover IRA. The Form 4 identifies ownership as indirect with the nature of ownership labeled as the rollover IRA, rather than shares being held directly by Marton Laurence personally.

How many RenovoRx (RNXT) shares does the insider hold after these transactions?

Following the transactions, the rollover IRA holds 9,720 common shares and 4,860 warrants, each warrant exercisable into one common share. These reported figures show the indirect holdings visible from this single Form 4 filing.

Were the RenovoRx (RNXT) insider transactions open-market purchases?

The transactions are coded as purchases, but a footnote specifies they occurred in a private placement on March 20, 2026. This indicates negotiated private financing terms rather than standard exchange-based open-market buying activity.